FLOWSHEET MODELING AND SIMULATION SOFTWARE LICENSE SUPPORT AND MAINTENANCE
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The U.S. Food and Drug Administration (FDA) is soliciting quotes for a new license for gPROMS or equal flowsheet modeling and simulation software, including model libraries and support. This is a combined synopsis/solicitation for commercial products or services. Quotes are due April 27, 2026.
Scope of Work
The objective is to acquire a flowsheet modeling and simulation platform (gPROMS or equal) with specific salient characteristics, including:
- Graphical interface with drag-and-drop functionality.
- Steady-state and dynamic process models for common pharmaceutical equipment.
- Custom modeling capabilities, parameter estimation, and global sensitivity analysis.
- Ability to estimate physical properties using databases like Multiflash or DIPPR.
- Specific model libraries for processes such as blending, granulation, milling, compression, tablet coating, oral absorption, crystallization, and drying.
The software will support the FDA's quality assessment of emerging continuous manufacturing technologies by characterizing material flow, residence time distribution, and variability propagation. It will also aid in understanding process dynamics, predicting impact of changes, supporting virtual experimentation, and evaluating control strategies.
Deliverables also include maintenance and technical support (software updates, one business-day response to defects) and one on-project training by the vendor.
Contract & Timeline
- Contract Type: Firm-Fixed-Price (FFP)
- Period of Performance: Base Year (07/12/2026 to 07/11/2027) with four Option Years (extending to 07/11/2031).
- Place of Performance: U.S. Food and Drug Administration Center for Drug Evaluation and Research, Silver Spring, MD.
- Set-Aside: Unrestricted, Full and Open Competition
- NAICS Code: 423430 (Computer and Computer Peripheral Equipment and Software Merchant Wholesalers)
- Quotes Due: April 27, 2026, 7:00 PM ET
- Published: April 20, 2026
Evaluation
Award will be made to the responsible quoter whose quote represents the best value to the Government, defined as Lowest Price Technically Acceptable (LPTA). Quotes must meet acceptability standards for technical and price factors. The Government intends to award without clarification or discussions.
Additional Notes
This announcement constitutes the only solicitation; a separate written solicitation will not be issued. The Government is not obligated to make an award or pay any costs incurred by the Contractor in preparing its quote. Quoters must submit a quote for all requirements (base and optional line items) and clearly state the overall quoted price.
Primary Contact: Robert Waite (robert.waite@fda.hhs.gov)